Omada Health, Inc. (OMDA)
NASDAQ:OMDA
OMDA Stock Chart & Stats
$11.41
-$4.40(-19.47%)
At close: 4:00 PM EDT
$11.41
-$4.40(-19.47%)
Day’s Range― - ―
52-Week Range$10.28 - $28.40
Previous Close$18.29
Volume2.54M
Average Volume (3M)1.48M
Market Cap
$672.34M
Enterprise Value$450.30M
Total Cash (Recent Filing)$222.04M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.78
Next Earnings
May 14, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.08
Shares Outstanding58,925,438
10 Day Avg. Volume724,586
30 Day Avg. Volume1,477,323
Financial Highlights & Ratios
PEG Ratio0.97
Price to Book (P/B)4.01
Price to Sales (P/S)3.54
P/FCF Ratio54.46
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue1.73
Enterprise Value/Gross Profit2.64
Enterprise Value/Ebitda-69.47
Forecast
1Y Price Target
$21.89Price Target Upside91.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.14
Revenue Forecast (FY)$318.89M
Bulls Say, Bears Say
Bulls Say
AI And Strategic PartnershipsAnalyst points to investments in AI, expansion of the GLP-1 companion program, and a partnership with a major pharmacy benefits manager as catalysts that can expand care tracking, boost member engagement, and drive revenue upside.
Product Pricing And MarginsAnalyst highlights the GLP-1 Flex Care offering allows employers to provide clinical support without covering drug costs while paying higher monthly fees, which should enhance pricing power and gross margins.
ProfitabilityAnalyst notes company achieved profitability on GAAP net income and adjusted EBITDA while generating positive free cash flow, indicating improving financial stability and lower reliance on external funding.
Bears Say
Earnings QualityAnalyst notes reported results included a one-time customer negotiation benefit that temporarily boosted revenue and EBITDA, raising concerns about the sustainability of reported growth.
Investment Impact On MarginsAnalyst warns planned increases in business investment could compress margins before corresponding revenue benefits are realized.
Sector Valuation HeadwindsAnalyst lowered the price target and cautions that broad valuation compression across the healthcare IT sector may keep the stock undervalued despite improving fundamentals.
Omada Health, Inc. News
OMDA FAQ
What was Omada Health, Inc.’s price range in the past 12 months?
Omada Health, Inc. lowest stock price was $10.28 and its highest was $28.40 in the past 12 months.
What is Omada Health, Inc.’s market cap?
Omada Health, Inc.’s market cap is $672.34M.
When is Omada Health, Inc.’s upcoming earnings report date?
Omada Health, Inc.’s upcoming earnings report date is May 14, 2026 which is in 31 days.
How were Omada Health, Inc.’s earnings last quarter?
Omada Health, Inc. released its earnings results on Mar 05, 2026. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.009 by $0.071.
Is Omada Health, Inc. overvalued?
According to Wall Street analysts Omada Health, Inc.’s price is currently Undervalued.
Does Omada Health, Inc. pay dividends?
Omada Health, Inc. does not currently pay dividends.
What is Omada Health, Inc.’s EPS estimate?
Omada Health, Inc.’s EPS estimate is -0.13.
How many shares outstanding does Omada Health, Inc. have?
Omada Health, Inc. has 58,925,438 shares outstanding.
What happened to Omada Health, Inc.’s price movement after its last earnings report?
Omada Health, Inc. reported an EPS of $0.08 in its last earnings report, beating expectations of $0.009. Following the earnings report the stock price went up 3.309%.
Which hedge fund is a major shareholder of Omada Health, Inc.?
Currently, no hedge funds are holding shares in OMDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Omada Health, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.89 (91.85% Upside)
$21.89 (91.85% Upside)
Blogger Sentiment
Bullish
OMDA Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 329.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Company Description
Omada Health, Inc.
Omada Health is a U.S.-based virtual-care provider offering clinically validated programs for chronic conditions like cardiometabolic disease, musculoskeletal care, and behavioral health—delivered digitally between doctor visits.
OMDA Company Deck
OMDA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong operational momentum in 2025 with substantial top-line growth (53%), scale in membership (886k, +55%), record margin expansion, first GAAP profitable quarter and positive full-year adjusted EBITDA—backed by product innovation (GLP-1 prescribing/Flex Care, cholesterol), AI deployment and peer-reviewed outcomes. Management provided prudent 2026 guidance (midpoint ~22% growth) that deliberately excludes early contributions from new products, which moderates near-term upside but reflects conservative planning. Near-term headwinds include seasonality-driven Q1 costs, a one-time Q4 revenue true-up, and the early-stage nature of new offerings; however, the balance of evidence points to durable commercial traction, improving unit economics and continued investment in scalable AI/product capabilities.View all OMDA earnings summariesOMDA Stock 12 Month Forecast
Average Price Target
$21.89
▲(91.85% Upside)
Technical Analysis
Acurx Pharmaceuticals
―
Healthcare Triangle
―
Bluejay Diagnostics
―
Tivic Health Systems
―
Heart Test Laboratories, Inc.
―
Ownership Overview
5.13% Insiders
4.45% Mutual Funds
43.67% Other Institutional Investors
44.90% Public Companies and
Individual Investors